Its been common knowledge for many years that a healthy diet lowers the chances of various cancers forming. Diets high of alkaline acid (as opposed to acidifying foods) are recommended for both cancer avoidance and as a cancer fighting diet.

Chillies which contain the chemical capsaicin, are an alkaline food. A recent study from Nottingham University (2) has shown that capsaicin kills lung cancer cells. Previous studies at the American Association for Cancer Research (1) had shown a similar effect with prostate cancer cells. Other studies in Japan and China have shown capsaicin directly inhibits the growth of leukemic cells.

Read more: Killing Cancer with Alkaline Diets of Hot Chilli

Read more: Adjustable Gastric Band

Acomplia has been approved in several countries. Its generic form is Rimonabant. This was created to help fight obesity and shows some promise to help out other ailments as well. One of them being, it is showing some potential to curb ones addition to cigarettes. Rimonabant has not yet been approved in the USA.

Acomplia (generic Rimonabant) diet pills offer some optimism for people suffering from obesity. It works differently from many other diet pills and has some benefits also not found with other weight loss medications. Studies show that it can increase levels of HDL which is more commonly known as "good cholesterol" while also reducing triglycerides or "bad cholesterol". And as mentioned, it may also one day be approved to be a useful smoking cessation. Simply put, Acomplia has been shown in studies to reduce a persons appetite. It works by blocking a cellular receptor in a part of the brain that is believed to influence the regulation of body weight, along with glucose and lipid metabolism.

Read more: Acomplia (Generic form Rimonabant)

There is still no official trademarked name for which Merck will most certainly obtain. It is still in the trial stages of development and testing but apparently Merck will apply to the FDA sometime 2008. If Taranabant makes it to the market that you will definately hear about it in the media.

Merck's pill is similar to rimonabant developed by Sanofi- Aventis SA, which failed to win backing from a U.S. regulatory panel last year because of increased suicide risk, a side effect not seen at the lower doses of Merck's drug. The company said it stopped testing the higher dose and has extended studies of taranabant to monitor psychological side effects.

Both the Merck and Sanofi drugs block a receptor in the brain and digestive system that researchers believe also makes marijuana smokers hungry. By turning off the mechanism, scientists believe they can suppress appetite.

Read more: Taranabant by Merck

Things To Avoid

Food may or may not contribute to an ulcer. Certain foods and drinks should be avoided if they make your ulcer pain worse. These include both regular and decaffeinated coffee, tea, chocolate, meat extracts, alcohol, black pepper, chili powder, mustard seed and nutmeg. But remember to keep a balanced diet. You can also try eating small, frequent meals when you're having pain. Also avoid anti-inflammatory drugs such as aspirin and ibuprofen. Caffeine seems to stimulate acid secretion in the stomach, which can aggravate the pain of an existing ulcer. However, the stimulation of stomach acid cannot be attributed solely to caffeine. Avoid alcohol. Although no proven link has been found between alcohol and peptic ulcers, ulcers are more common in people who have cirrhosis of the liver, a disease often linked to heavy alcohol consumption. Avoid smoking. Studies show smoking increases the chances of getting an ulcer, slows the healing process of existing ulcers, and contributes to ulcer recurrence

Read more: Dietry Tips For Stomach Ulcers

SAN DIEGO, Dec 08, 2008 - Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today publication of the Phase 2b clinical trial results of lorcaserin, its novel drug candidate for the treatment of obesity, in the December 4, 2008 issue of Obesity, the official peer reviewed journal of The Obesity Society. In this randomized, double-blind, placebo-controlled trial, patients treated with lorcaserin, as compared to placebo, experienced statistically significant greater weight loss, with a significantly greater proportion of patients losing at least 5% of their weight over a 12-week period. Weight changes of this magnitude have been shown to improve cardiovascular risk factors such as blood pressure and dyslipidemia, and to significantly reduce the risk of developing diabetes in patients with glucose intolerance. Improvements in other endpoints were also achieved, including decreases in cholesterol and waist circumference. Lorcaserin was well tolerated in all dose groups.

"The weight loss results demonstrated by lorcaserin in the Phase 2b clinical trial, coupled with the compound's highly selective mechanism and good tolerability, provide reason for optimism for the millions of Americans struggling with the obesity epidemic," commented Steven R. Smith, M.D., principal investigator in the study and Assistant Director for Clinical Research at the Pennington Biomedical Research Center. "As a clinician faced with the challenge of helping a growing number of patients safely lose weight, I am acutely aware of the need for novel treatment options and I am hopeful that lorcaserin will prove successful at addressing that need."

Read more: Lorcaserin Phase 2b Clinical Trial Results Published in Obesity